Maki Kiso

12.9k total citations · 4 hit papers
85 papers, 4.9k citations indexed

About

Maki Kiso is a scholar working on Epidemiology, Infectious Diseases and Immunology. According to data from OpenAlex, Maki Kiso has authored 85 papers receiving a total of 4.9k indexed citations (citations by other indexed papers that have themselves been cited), including 59 papers in Epidemiology, 40 papers in Infectious Diseases and 19 papers in Immunology. Recurrent topics in Maki Kiso's work include Influenza Virus Research Studies (53 papers), Respiratory viral infections research (41 papers) and SARS-CoV-2 and COVID-19 Research (25 papers). Maki Kiso is often cited by papers focused on Influenza Virus Research Studies (53 papers), Respiratory viral infections research (41 papers) and SARS-CoV-2 and COVID-19 Research (25 papers). Maki Kiso collaborates with scholars based in Japan, United States and Vietnam. Maki Kiso's co-authors include Yoshihiro Kawaoka, Yuko Sakai‐Tagawa, S. Yamada, Yasuo Suzuki, Norio Sugaya, Keiko Mitamura, Chiharu Kawakami, Makoto Ozawa, Kyoko Shinya and Kazuhiro Kimura and has published in prestigious journals such as Nature, Proceedings of the National Academy of Sciences and The Lancet.

In The Last Decade

Maki Kiso

81 papers receiving 4.7k citations

Hit Papers

Experimental adaptation of an influenza H5 HA confers r... 2004 2026 2011 2018 2012 2004 2005 2024 250 500 750 1000
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Experimental adaptation of an influenza H5 HA confers respiratory droplet transmission to a reassortant H5 HA/H1N1 virus in ferrets
    2012 1.1k citations Masaki Imai, Tokiko Watanabe et al. profile →
  2. Resistant influenza A viruses in children treated with oseltamivir: descriptive study
    2004 611 citations Maki Kiso, Yuko Sakai‐Tagawa et al. profile →
  3. Isolation of drug-resistant H5N1 virus
    2005 575 citations Maki Kiso, Kazuhiko Someya et al. profile →
  4. A human isolate of bovine H5N1 is transmissible and lethal in animal models
    2024 52 citations Tadashi Maemura, Maki Kiso et al. profile →

Peers

Maki Kiso
Xiyan Xu United States
Makoto Ozawa Japan
Darwyn Kobasa Canada
Peter Halfmann United States
John C. Kash United States
Michael W. Shaw United States
Larisa V. Gubareva United States
Takato Odagiri Japan
Tokiko Watanabe Japan
Kyoko Shinya Japan
Xiyan Xu United States
Maki Kiso
Citations per year, relative to Maki Kiso Maki Kiso (= 1×) peers Xiyan Xu

Countries citing papers authored by Maki Kiso

Since Specialization
Citations

This map shows the geographic impact of Maki Kiso's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Maki Kiso with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Maki Kiso more than expected).

Fields of papers citing papers by Maki Kiso

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Maki Kiso. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Maki Kiso. The network helps show where Maki Kiso may publish in the future.

Co-authorship network of co-authors of Maki Kiso

This figure shows the co-authorship network connecting the top 25 collaborators of Maki Kiso. A scholar is included among the top collaborators of Maki Kiso based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Maki Kiso. Maki Kiso is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Uraki, Ryuta, Mutsumi Ito, Maki Kiso, et al.. (2025). An XBB.1.5-based inactivated SARS-CoV-2 vaccine partially protects against XBB.1.5 and JN.1 strains in hamsters. PubMed. 3(1). 7–7.
2.
Uraki, Ryuta, Maki Kiso, Mutsumi Ito, et al.. (2025). An mRNA vaccine encoding the SARS-CoV-2 Omicron XBB.1.5 receptor-binding domain protects mice from the JN.1 variant. EBioMedicine. 117. 105794–105794. 1 indexed citations
3.
Mountford, Simon J., Maki Kiso, Danielle E. Anderson, et al.. (2025). Targeted protein degraders of SARS-CoV-2 Mpro are more active than enzymatic inhibition alone with activity against nirmatrelvir resistant virus. Communications Medicine. 5(1). 140–140. 5 indexed citations
4.
Kiso, Maki, Seiya Yamayoshi, Yoshiki Yamaguchi, et al.. (2025). G-quadruplex-forming small RNA inhibits coronavirus and influenza A virus replication. Communications Biology. 8(1). 27–27.
5.
Furusawa, Yuri, Maki Kiso, Ryuta Uraki, et al.. (2025). Amino acid substitutions in NSP6 and NSP13 of SARS-CoV-2 contribute to superior virus growth at low temperatures. Journal of Virology. 99(3). e0221724–e0221724.
6.
Ueki, Hiroshi, Maki Kiso, Yuri Furusawa, et al.. (2024). Development of a Mouse-Adapted Reporter SARS-CoV-2 as a Tool for Two-Photon In Vivo Imaging. Viruses. 16(4). 537–537. 2 indexed citations
7.
Uraki, Ryuta, Masaki Imai, Mutsumi Ito, et al.. (2024). An mRNA vaccine encoding the SARS-CoV-2 receptor-binding domain protects mice from various Omicron variants. npj Vaccines. 9(1). 4–4. 7 indexed citations
8.
Chiba, S., Maki Kiso, S. Yamada, et al.. (2024). An mRNA vaccine candidate encoding H5HA clade 2.3.4.4b protects mice from clade 2.3.2.1a virus infection. npj Vaccines. 9(1). 189–189. 6 indexed citations
9.
Halfmann, Peter, Kiyoko Iwatsuki‐Horimoto, Makoto Kuroda, et al.. (2024). Characterization of Omicron BA.4.6, XBB, and BQ.1.1 subvariants in hamsters. Communications Biology. 7(1). 331–331. 6 indexed citations
10.
Kiso, Maki, Seiya Yamayoshi, Shun Iida, et al.. (2023). In vitro and in vivo characterization of SARS-CoV-2 resistance to ensitrelvir. Nature Communications. 14(1). 4231–4231. 38 indexed citations
11.
Kiso, Maki, Yuri Furusawa, Ryuta Uraki, et al.. (2023). In vitro and in vivo characterization of SARS-CoV-2 strains resistant to nirmatrelvir. Nature Communications. 14(1). 3952–3952. 22 indexed citations
12.
Kiso, Maki, Ryuta Uraki, Mutsumi Ito, et al.. (2023). Oral intake of heat-killed Lactiplantibacillus pentosus ONRICb0240 partially protects mice against SARS-CoV-2 infection. SHILAP Revista de lepidopterología. 3. 2 indexed citations
13.
Chiba, S., Maki Kiso, Noriko Nakajima, et al.. (2022). Co-administration of Favipiravir and the Remdesivir Metabolite GS-441524 Effectively Reduces SARS-CoV-2 Replication in the Lungs of the Syrian Hamster Model. mBio. 13(1). e0304421–e0304421. 23 indexed citations
14.
Yasuhara, Atsuhiro, Seiya Yamayoshi, Maki Kiso, et al.. (2022). A broadly protective human monoclonal antibody targeting the sialidase activity of influenza A and B virus neuraminidases. Nature Communications. 13(1). 6602–6602. 26 indexed citations
15.
Takamatsu, Yuki, Masaki Imai, Kenji Maeda, et al.. (2021). Highly Neutralizing COVID-19 Convalescent Plasmas Potently Block SARS-CoV-2 Replication and Pneumonia in Syrian Hamsters. Journal of Virology. 96(4). e0155121–e0155121. 16 indexed citations
16.
Watanabe, Tokiko, Kiyoko Iwatsuki‐Horimoto, Maki Kiso, et al.. (2018). Experimental infection of Cynomolgus Macaques with highly pathogenic H5N1 influenza virus through the aerosol route. Scientific Reports. 8(1). 4801–4801. 9 indexed citations
17.
Iwatsuki‐Horimoto, Kiyoko, Noriko Nakajima, Masatoshi Shibata, et al.. (2016). The Microminipig as an Animal Model for Influenza A Virus Infection. Journal of Virology. 91(2). 18 indexed citations
18.
Uraki, Ryuta, Subash C. Das, Masato Hatta, et al.. (2014). Hemozoin as a novel adjuvant for inactivated whole virion influenza vaccine. Vaccine. 32(41). 5295–5300. 12 indexed citations
19.
Kiso, Maki, Ryo Takano, Saori Sakabe, et al.. (2013). Protective efficacy of orally administered, heat-killed Lactobacillus pentosus b240 against influenza A virus. Scientific Reports. 3(1). 1563–1563. 49 indexed citations
20.
Horimoto, Taisuke, Shin Murakami, Yukiko Muramoto, et al.. (2007). Enhanced growth of seed viruses for H5N1 influenza vaccines. Virology. 366(1). 23–27. 44 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Xiyan Xu Breakdown of academic impact, for papers by Makoto Ozawa Breakdown of academic impact, for papers by Darwyn Kobasa Breakdown of academic impact, for papers by Peter Halfmann Breakdown of academic impact, for papers by John C. Kash Breakdown of academic impact, for papers by Michael W. Shaw Breakdown of academic impact, for papers by Larisa V. Gubareva Breakdown of academic impact, for papers by Takato Odagiri Breakdown of academic impact, for papers by Tokiko Watanabe Breakdown of academic impact, for papers by Kyoko Shinya
Rankless by CCL
2026